Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome

Authors

• Md Shadman Ridwan Abid, University of Nebraska-LincolnFollow
• Haowen Qiu, University of Nebraska-Lincoln
• Bridget A. Tripp, University of Nebraska-Lincoln
• Aline De Lima Leite, University of Nebraska-Lincoln
• Heidi Roth, University of Nebraska-Lincoln
• Jiri Adamec, University of Nebraska-LincolnFollow
• Robert Powers, University of Nebraska - LincolnFollow
• James W. Checco, University of Nebraska-LincolnFollow

Date of this Version

4-11-2022

Document Type

Presentation

Comments

Copyright © 2022 by the authors

Abstract

Interstitial cystitis or bladder pain syndrome (IC/BPS) is a chronic and debilitating pain disorder of the bladder and urinary tract with poorly understood etiology. Symptomatic criteria to aid in the diagnosis of IC/BPS includes bladder pain, an increase in urinary urgency or Hunner’s ulcers on the bladder wall.

Our study revealed differences in the profiles of small urinary peptides for IC/BPS patients compared to age-matched controls which is consistent with increased protease activity in IC/BPS. Our study also enabled the direct measurement of APF peptide abundance in IC/BPS and control urine. Our results indicate that the full-length APF peptide was not consistently found in the urine of IC/BPS patients at levels sufficient to reliably differentiate IC/BPS patients from healthy individuals.